

# **Perinatal Arterial Stroke(PAS): A Multi-site RCT of Intensive Infant Rehabilitation (I-ACQUIRE)**

**Warren Lo, M.D.,**

**Nationwide Children's Hospital & The Ohio State University**

**Sharon Landesman Ramey, Ph.D.,**

**Virginia Tech Carilion Research Institute, Virginia Tech (Roanoke)**

**Stephanie DeLuca PhD, Amy Darragh PhD, Jill Heathcock, PhD,**

**Max Wintermark MD, and Craig Ramey, PhD**

**StrokeNet Meeting**

**October 16, 2018**

**Montreal, PQ**

## BACKGROUND FOR I-ACQUIRE

- Pediatric arterial ischemic stroke occurs most frequently in infants
  - Estimated incidence of neonatal stroke 1:2500 – 1:7700 live births
  - Incidence of presumed perinatal stroke likely similar
- No consensus rehabilitation for infants with post-stroke hemiplegia
  - Wide array of approaches
    - Weekly low-dose therapy is typical (not evidence-based)
    - Consensus from systematic reviews that constraint-induced movement therapy (CIMT) efficacious in older children with hemiparesis
      - CIMT is considered high-intensity and actively shapes voluntary control
  - No adequately powered RCT of CIMT in infants (< 24 mos)
  - No RCT of signature CIMT focused on infants after stroke
- Our team developed safe & feasible pediatric constraint (CIMT) protocol – known as ACQUIREc (DeLuca, Ramey, & Echols [2006])
  - High therapy dosage of 3 or 6 hrs/day X 20 days
  - Operant conditioning techniques utilizing infant principles of learning
    - Individualized activities & reinforcements, both uni- and bimanual
    - Parents included in treatment planning and delivery

## PUBLIC HEALTH IMPACT OF I-ACQUIRE PHASE III TRIAL

- In U.S., 3400+ new cases/year of Perinatal Arterial Stroke (PAS)
- High likelihood of lifelong motor and cognitive impairments, especially hemiparesis
- Immense cost burden for families, the healthcare and education systems, and society

*If I-ACQUIRE(at one or both doses) proves efficacious,  
then the field will have the critically needed Phase III  
confirmatory evidence to transform rehabilitation and  
improve clinical outcomes for infants with PAS.*

## I-ACQUIRE SPECIFIC AIMS

- **Primary Aim:** Determine the efficacy of I-ACQUIRE at 2 dosage levels compared to U&CT to increase upper extremity skills on the hemiparetic side.
- **Secondary Aim:** Determine the efficacy of I-ACQUIRE at 2 dosage levels compared to U&CT to improve use of the hemiparetic upper extremity in bimanual activities.
- **Exploratory Aim:** Explore the association between I-ACQUIRE treatment at Moderate and High Doses and gross motor development and cognition (i.e., cross-domain effects of treatment).

# **DESIGN FOR PHASE III I-ACQUIRE**

## **Eligibility Screening and Enrollment (N=240)**

Perinatal Arterial Stroke (PAS) diagnosis  
with confirmatory MRI & hemiparesis (8–24 mos)

## **Random Assignment (centralized) to I-ACQUIRE DOSAGE GROUPS**

**Moderate Dose  
I-ACQUIRE  
(N=80)  
3 hr/day x 20**

**High Dose  
I-ACQUIRE  
(N=80)  
6 hr/day x 20**

**Usual &  
Customary Tx  
(UCT) (N=80)  
documented**

## **Baseline (pre-treatment) Assessment Battery**

Blinded Assessments (video) & Parent Ratings

## **Implementation of Treatment Protocol (4 weeks)**

Active Central Monitoring & Therapy Logs

## **Post-treatment Assessment Battery: Immediate & 6 mos.**

Blinded Assessments (video) & Parent Ratings

UCT Parents offered choice of  
I-ACQUIRE Dosage (Crossover)

## **DETAILS ABOUT ENROLLMENT FOR I-ACQUIRE**

- **Inclusion criteria:**

- 8-24 mos old
- Perinatal AIS confirmed with clinical MRI (high-quality, standardized)
- Hemiparesis at mini-MACS II, III, or IV level
- Parents able to participate in home-based intervention and parent Tx component
  - present at least 1 day/wk for therapy and 40-60 min/day at home

- **Exclusion Criteria:**

- Fragile medical health, prior receipt of CIMT  $\geq$  2 hrs/day  $\times$  10 days, Botox within 3 mos

- **In prior studies of ACQUIRE, parent willingness to enroll is high (93-95%) and attrition rate is low (5-7%)**

- Most attrition occurs prior to starting treatment (reasons not related to Tx)
- After starting treatment, attrition about 3% in current trials


## **GOING FORWARD**

- **Identify 12-13 sites with interest, resources, patient volumes**
  - Access to research therapists/assessors – **We will help through our national network with OTs and PTs**
  - Anticipated ability to recruit 20 subjects/site over study duration of 3.5 yrs
  - Willing to go to homes or have available home-like facilities where out-of-town families can live for 4 weeks (e.g., extended stay hotels, furnished apartments, Ronald McDonald house) Note: Proposal does not have funding to pay for lodging
- **Anticipate training therapists and assessors for 6-7 sites at onset then remaining sites after 9-12 months into the project; Travel and salary needed for training are covered by the grant**
- **Eager to meet with new StrokeNet sites and existing sites to have individualized conversations; Copy of the full grant application is available for all who are interested.**

## MANY THANKS FOR GUIDANCE AND SUPPORT

- **StrokeNet Leadership:** Joseph Broderick
- **Rehabilitation Working Group:** Steven Cramer, Steven Wolf, and multiple members of the working group
- **StrokeNet DMSC:** Caitlin Meinzer, Renee Martin, and Yuko Palesch
- **NINDS:** Scott Janis

Number of New Skills Gained After I-ACQUIRE  
on the Emerging Behaviors Scale  
(27 Infants with Hemiparesis)



# **I-ACQUIRE**

## **CORE TREATMENT COMPONENTS**

- Constraint of the infant's less-impaired upper extremity for first 17 days of 20 treatment; cast is worn continuously
- High dosages of treatment – either 3 or 6 hrs/day, 5 days/wk for 4 weeks
- Operant conditioning techniques to shape and improve skills and abilities, combined with practice variation
- Provision of therapy in natural settings
- Emphasis on total body and bimanual activities (as well as traditional arm/hand therapy activities)
- Active Parent-Therapist Partnership
- Documentation of daily therapy sessions
- Transfer Package to promote future skill and motor development